EXPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 BY HUMAN PROSTATE CARCINOMA-CELLS INHIBITS PRIMARY TUMOR-GROWTH, TUMOR-ASSOCIATED ANGIOGENESIS, AND METASTASIS TO LUNG AND LIVER IN AN ATHYMIC MOUSE MODEL
Ga. Soff et al., EXPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 BY HUMAN PROSTATE CARCINOMA-CELLS INHIBITS PRIMARY TUMOR-GROWTH, TUMOR-ASSOCIATED ANGIOGENESIS, AND METASTASIS TO LUNG AND LIVER IN AN ATHYMIC MOUSE MODEL, The Journal of clinical investigation, 96(6), 1995, pp. 2593-2600
Expression of urokinase-type plasminogen activator (uPA) by malignant
cells correlates with an aggressive phenotype, including increased inv
asiveness, tumor-associated angiogenesis, and metastases, Plasminogen
activator inhibitor type 1 (PAI-1) is undetectable in cells of some ag
gressive malignancies, but present in the stroma of tumor-associated m
icrovasculature, This analysis of an athymic mouse model of prostate c
arcinoma further defines the role of the uPA/PAI-1/plasmin system in p
rimary growth and metastasis. A marked increase in PAI-1 expression wa
s induced in clones of the aggressive human prostate carcinoma line, P
C-3, by stable transfection. Primary PC-3 tumors, in mice, were signif
icantly smaller when derived from PAI-1 expressing versus control cell
s, PAI-1 expression reduced the density of tumor-associated microvascu
lature by 22-38%, Microscopic metastases were quantitated using stable
expression of the chromogenic label (beta-galactosidase) in control a
nd PAI-1 expressing cells, PAI-1 expression resulted in a significant
inhibition of lung metastases, and liver metastases, Expression of PAI
-1 by malignant prostate cells resulted in a less aggressive phenotype
, presumably by inhibition of uPA activity, suggesting pharmacologic o
r molecular inhibition of uPA activity as a potential therapeutic targ
et.